Medibank Private (ASX:MPL) share price dips despite 27% profit boost

The Medibank Private Limited (ASX:MPL) share price is down today, despite the release of strong half-yearly results for FY20 from the insurer.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Medibank Private Ltd (ASX: MPL) shares are under pressure today following the release of the insurer's half-yearly results for FY21.

At the time of writing, the Medibank share price has dipped to $2.83, down 2.08%.

ASX share price movement represented by doctor pressing digitised screen with array of icons including one entitled health insurance,

Image source: Getty Images

What did Medibank announce today?

The private health insurance provider announced a net profit after tax of $226.4 million for the 6 months ending 31 December 2020 – a 27.3% increase compared to the prior corresponding period (pcp).

The company attributed the increased profit primarily to a net gain of 49,000 policy holders over the period. 17,600 of these new customers signed up for Medibank-branded insurance itself.

"This is the first time we have grown the Medibank brand in any 6-month period since 2013 and this trend has continued into February," the company said in a media release today.

Medibank's results stand in stark contrast to the private health insurance industry at large. According to the Australian Prudential Regulatory Authority, industry profitability was down by 2 percentage points on the pcp — driven largely by the COVID-19 pandemic.

The pandemic led many private health insurance providers, including Medibank, to postpone premium increases for 6 months. Medibank stated the postponement cost the company $109 million in revenue. Despite this, revenue from premiums did rise 0.3% to $3.3 billion.

In further good news for shareholders, net claims expenses also decreased by 0.8% compared to the pcp, or $24.1 million. Gross claims fell by 1.8%, including a $99 million COVID-related reduction in claims and risk equalisation payable for the period. Underlying claims, adjusted for COVID impacts and provision movements, rose by 2.6%.

The company announced a dividend of 5.8 cents per share fully franked.

Medibank CEO to retire

Along with today's financial announcements, Medibank Private CEO Craig Drummond announced he is retiring from the position come 30 June.

Mr Drummond made the following comments about the results release and his impending retirement.

"Pleasingly Medibank is on a clear strategic path to grow the private health insurance business at a faster rate and continue its transformation into a broader healthcare company."

"Leading Medibank through this transition has been incredibly rewarding."

The Medibank share price during Mr Drummond's tenure saw a modest decline – starting around $3 when he first started while opening this morning at $2.89. During his time, Medibank shares hit a high of $3.65 and a low of $2.33.

Future outlook

Medibank is continuing its investment in healthcare. The company also announcing an expansion of its no gap joint replacement pilot into 6 regions. The pilot is a part of the company's investment into a 'short-stay model of care' program – a long-term venture aiming to reduce hospital-related expenses for both customer and company.

As of 15 February, Medibank Private is still the leading private health insurance company in Australia with a 26.9% market share and 3.7 million customers, according to comparison site ComparingExpert.

Motley Fool contributor Marc Sidarous has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

Rising ASX uranium share price icon on a stock index board.
Broker Notes

Why ASX uranium shares like Paladin and Boss Energy could be set to rocket

A top broker expects Boss Energy, Paladin, and these three ASX uranium stocks to outperform. But why?

Read more »

Red buy button on an apple keyboard with a finger on it representing asx tech shares to buy today
Broker Notes

Broker names 3 ASX 200 shares to buy in March

Let's see why these shares are being tipped as buys this month.

Read more »

A panel of four judges hold up cards all showing the perfect score of ten out of ten
Share Gainers

Here are the top 10 ASX 200 shares today

Investors caught a break with a decent recovery from the markets today.

Read more »

A young man punches the air in delight as he reacts to great news on his mobile phone.
Broker Notes

Why this cheap ASX 200 stock could rise 80%

Bell Potter thinks this stock could be destined to surge.

Read more »

Disappointed man with his head on his hand looking at a falling share price his a laptop.
Share Fallers

Why BHP, EQ Resources, Lottery Corp, and Woodside shares are falling today

These shares are struggling on Thursday. Let's find out why.

Read more »

Happy work colleagues give each other a fist pump.
Share Gainers

Why Endeavour, Lindian, Magellan, and WiseTech shares are storming higher today

These shares are catching the eye on Thursday. Let's see why they are rising.

Read more »

Man on a laptop thinking.
Broker Notes

Buy, hold, sell: Endeavour, Life360, and Lynas shares

Let's see what the broker is saying about these shares this week.

Read more »

A doctor looks unsure.
Opinions

3 reasons why the CSL share price could leap 87% to $274!

Here's what to expect from the Biotech stock next.

Read more »